Natural immunity has significant impact on immune responses against cancer

Scandinavian Journal of Immunology

Volumn 69, Issue 3, 2009, Pages 275-290

  Rubin, B ^a,b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLGLUTAMYLMETHIONYLLEUCYLASPARAGINYLSERYLSERYLPHENYL ALANYLSERYLTHREONYLLEUCYLLYSINE; CANCER ANTIBODY; CD2 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOMYCIN C; PEPTIDE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER GROWTH; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL DEATH; CELL MATURATION; CELL TRANSFORMATION; CELLULAR IMMUNITY; DENDRITIC CELL; IMMUNE SYSTEM; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGICAL MEMORY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; LYMPHOMA; MACROPHAGE; MICROORGANISM; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; THYMUS; TUMOR IMMUNITY;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 60349099459     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02220.x     Document Type: Review

References (86)

1. Rubin B, Wigzell H. The immune response against hapten-autologous protein conjugates in the mouse. III. Specificity of cooperating non-thymus processed (B) and thymus processed (T) lymphocytes. J Exp Med 1973 137 : 911 27.
2. Rubin B, Wigzell H. On the nature of hapten reactive helper lymphocytes. Nature 1973 242 : 467 9.
3. Rubin B, Hertel-Wulff B, Kimura A. Alloantigen-specific idiotype-bearing receptors on mouse T lymphocytes. I. Specificity characterization and genetic association with the heavy chain IgG allotype. J Exp Med 1979 150 : 307 20.
4. Rubin B, Bourgois A. Rabbit antisera with specificity for isolated mouse T lymphocyte receptors. Scand J Immunol 1981 14 : 167 82.
5. Rubin B, Alibaud L, Champagne A, Arnaud J, Toribio ML. Some hints concerning the shape of T-cell receptor structures. Scand J Immunol 2002 55 : 111 8.
6. Rubin B, Diaz de Durana Y, Li C, Sercarz EE. Regulatory cells: Specific for antigen or antigen receptors. Scand J Immunol 2003 57 : 399 409.
7. + T cells inhibit T cell lymphoma growth in vivo. J Immunol 2004 173 : 7062 9.
8. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989 54 : 1 13.
9. Krogsgaard M, Davis MM. How T cells "see" antigen. Nature Immunol 2005 6 : 239 45.
10. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Ann Rev Immunol 2006 24 : 419 66.
11. Gil D, Schrum AG, Alarcon B, Palmer E. T-cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J Exp Med 2005 201 : 517 22.
12. Graber M, Bockenstedt LK, Weiss A. Signaling via the inositol phospholipid pathway by T cell antigen receptor is limited by receptor number. J Immunol 1991 146 : 2935 43.
13. Germain RN. The T cell receptor for antigen: signaling and ligand discrimination. J Biol Chem 2001 276 : 35223 6.
14. Montixi C, Langlet C, Bernard AM et al. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J 1998 17 : 5334 48.
15. van der Merwe PA, Davis SJ. Molecular interactions mediating T-cell antigen recognition. Ann Rev Immunol 2003 21 : 659 84.
16. Rubin B, Knibiehler M, Gairin JE. Allosteric changes in the TCR/CD3 structure upon interaction with extra- or intra-cellular ligands. Scand J Immunol 2007 66 : 228 37.
17. Huppa JB, Davis MM. T-cell antigen recognition and the immunological synapse. Nat Rev Immunol 2003 3 : 973 83.
18. Naeher D, Daniels MA, Hausmann B, Guillaume P, Luescher I, Palmer E. A constant affinity threshold for T cell tolerance. J Exp Med 2007 204 : 2553 9.
19. Wilson SS, van den Elzen P, Maverakis E et al. Residual public repertoires to self. J Neuroimmunol 2000 107 : 233 9.
20. + regulatory T cells for immunological self-tolerance and negative control of immune responses. Ann Rev Immunol 2004 22 : 531 62.
21. Tanigushi M, Seino KI, Nakayama T. The NKT cell system: Bridging innate and acquired immunity. Nature Immunol 2003 4 : 1164 5.
22. Borg NA, Wun KS, Kjer-Nielsen L et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007 448 : 44 9.
23. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005 435 : 598 604.
24. Rubin B, Alibaud L, Huchenq-Champagne A, Arnaud J, Toribio ML. Some hints concerning the shape of T-cell receptor structures. Scand J Immunol 2002 55 : 111 8.
25. Szymczak AL, Workman CR, Gil D et al. The CD3ε proline-rich sequence, and its interaction with Nck, is not required for T cell development and function. J Immunol 2005 175 : 270 5.
26. Tailor P, Tsai S, Shameli A et al. The proline-rich sequence of CD3ε as an amplifier of low-avidity TCR signaling. J Immunol 2008 181 : 243 55.
27. Becker AM, deFord-Watts L, Wuelfing C, van Oers NSC. The constitutive tyrosine phosphorylation of CD3* results from TCR-MHC interactions that are independent of thymic selection. J Immunol 2007 178 : 4120 8.
28. Huseby ES, White J, Crawford F et al. How the T cell repertoire becomes peptide and MHC specific. Cell 2005 122 : 247 60.
29. Felix NJ, Donermeyer DL, Horvath S et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nature Immunol 2007 8 : 388 97.
30. + medullary thymic epithelial cells. Nature Immunol 2007 8 : 351 8.
31. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 3 : 23 35.
32. Moody DB, Porcelli S. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol 2002 3 : 11 22.
33. Schurr M, Chen Q, Shin A et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005 105 : 2465 72.
34. Blander JM, Medzhikov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006 440 : 808 12.
35. Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007 219 : 143 56.
36. Graham DB, Stephenson LM, Lam SK et al. An ITAM-signaling pathway controls cross-presentation of particulate but not soluble antigens in dendritic cells. J Exp Med 2007 204 : 2889 97.
37. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007 28 : 429 36.
38. Rubin B, Cooley MA, Le Borgne De Kaouel C, Taylor RB, Golstein P. A fetal calf serum-specific cell line that induces T- and B-cell differentiation.Scand. J Immunol 1980 12 : 401 9.
39. Suzan M, Bourgois A, Boned A, De Preval C, Golstein P, Rubin B. Analysis of a fetal calf serum induced T cell line. I. H-2 restricted growth and expression of membrane-bound and released molecules bearing 5936-idiotypic determinants. J Immunol 1981 127 : 992 9.
40. Wegener AMK, Holm B, Geisler C, Rubin B. Cellular and molecular characteristics of transformed T cells from an antigen-specific T-cell line. Scand J Immunol 1990 31 : 645 55.
41. Rubin B, Gonthier M, Llobera R, Arnaud J. Two discrete functions of T cell antigen receptors in regulation of autoimmunity: ligands and receptors. Curr Trends Immunol 2004 31 : 109 21.
42. Rubin B, Reininger L, Suzan M et al. On the molecular basis of T helper cell function. III. B-lymphocyte promotor factors: production by T hybridoma and tumor cells; preliminary biochemical characterization. Scand J Immunol 1984 19 : 563 73.
43. + T cells inhibit T cell lymphoma growth in vivo. J Immunol 2004 173 : 7062 9.
44. + T cells. Immunity 2005 22 : 371 83.
45. Golstein P, Luciani MF, Rubin B. Xenogeneic serum-induced mouse T cells that trigger the differentiation of precursor into cytolytic T cells. J Immunol 1980 125 : 1144 51.
46. Benjamini E, Fong S, Erikson C, Leung CY, Rennick D, Scibienski RJ. Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin C-treated cells. J Immunol 1977 118 : 685 93.
47. Rubin B. Antigen recognition by subpopulations of T lymphocytes. A review with special reference to the development of viral and bacterial vaccines. Acta Pathol Microbiol Scand Sect C 1977 88 : 319 28.
48. Caspar-Bauguil S, Arnaud J, Gouaillard C, Hou X, Geisler C, Rubin B. Functionally important amino acids in T cell antigen receptors revealed by immunoselection of TCR/CD3 negative T cells. J Immunol 1994 152 : 5288 98.
49. Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999 50 : 213 20.
50. Avrameas S, Ternynck T, Tsonis IA, Lymberi P. Naturally occurring B-cell autoreactivity: a critical review. J Autoimmun 2007 29 : 213 8.
51. Jerne NK. Idiotype networks and other preconceived ideas. Immunol Rev 1984 79 : 5 24.
52. Forni L, Coutinho A, Köhler G, Jerne NK. IgM antibodies induce the production of antibodies of the same specificity. Proc Natl Acad Sci USA 1980 77 : 1125 8.
53. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993 72 : 551 60.
54. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephamyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994 78 : 399 408.
55. Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 1998 161 : 2187 94.
56. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001 1 : 135 45.
57. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989 54 : 1 13.
58. Carnaud C, Lee D, Donnars O et al. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999 163 : 4647 50.
59. Fernandez NC, Lozier A, Flamant C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med 1999 5 : 405 11.
60. Smyth MJ, Godfrey DI. NKT cells and tumor immunity - a double-edged sword. Nat Immunol 2000 1 : 459 60.
61. Rubin B. In Autoimmunity: Role, Regulation and Disorders. Ed. Vogel FL Zimmermann LF. Nova Science Publishers 2008.
62. low tumor cells. Cancer Immun 2008 8 : 14 25.
63. Cooke A, Zaccone P, Raine T, Phillips JM, Dunne DW. Infection and autoimmunity: are we winning the war, only to lose the peace? Trends Parasitol 2004 20 : 316 21.
64. Kalinski P, Moser M. Consensual immunity: success-driven development of Th1 and Th2 responses. Nat Rev Immunol 2005 5 : 251 60.
65. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007 81 : 1 5.
66. Prehn RT, Prehn LM. The flip side of immune surveillance: immune dependency. Immunol Rev 2008 222 : 341 56.
67. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006 6 : 24 37.
68. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001 167 : 5247 53.
69. Garbi N, Arnold B, Gordon S, Hämmerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004 172 : 5861 9.
70. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007 56 : 227 36.
71. Dunn GP, Old LJ, Schreiber RD. The three aces of cancer immunoediting. Ann Rev Immunol 2004 22 : 329 60.
72. Ganss R, Arnold B, Hämmerling GJ. Overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 2004 34 : 2635 41.
73. + effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003 170 : 4427 31.
74. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001 61 : 1095 9.
75. Yee C, Greenberg P. Modulating T-cell immunity to tumors: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002 2 : 409 19.
76. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007 25 : 267 96.
77. Entin I, Plotnikov G, Keisari Y. Tumor growth retardation, cure, and induction of anti-tumor immunity in B16 melanoma-bearing mice by mow electric field-enhanced chemotherapy. Clin Cancer Res 2003 9 : 3190 7.
78. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. Inhibition of B16 melanoma experimental metastasis by intereferon-γ through direct inhibition of cell proliferation and activation of anti-tumour host mechanisms. Immunology 2002 105 : 92 100.
79. Cui Z, Willingham MC, Hicks AM et al. Spontaneous regression of advanced cancer: identification of a unique genetically determined trait in mice. Proc Natl Acad Sci USA 2003 100 : 6682 7.
80. Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, Cui Z. Effector mechanisms of the anti-cancer immune response of macrophages in SR/CR mice. Cancer Immun 2006 6 : 11 20.
81. MacDonald AS, Maizels RM. Alarming dendritic cells for Th2 induction. J Exp Med 2008 205 : 13 7.
82. Mocikat R, Braumüller H, Gumy A et al. Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003 19 : 561 9.
83. Uno T, Takeda K, Kojima Y et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nature Med 2006 12 : 693 8.
84. Kim KD, Zhao J, Auh S et al. Adaptive immune cells temper initial innate responses. Nature Med 2007 13 : 1248 52.
85. Stubbs AC, Martin KS, Coesshott C et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nature Med 2001 7 : 625 9.
86. Franzusoff A, Duke RC, King TH, Lu Y, Rodell TC. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 2005 5 : 565 75.